Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR_PAC: ATRA + Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer
NCT03307148Phase 1Completed
- Sponsor
- Barts Health NHS Trust
- Start
- Jan 2016
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tretinoin in pancreatic adenocarcinoma (PDAC), sponsored by Barts Health NHS Trust. Primary endpoints: Dose Limiting Toxicities at 28 days and Optimum Biological Dose. Started Jan 2016; status: completed.
02
Drugs
tretinoin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03307148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03307148.